EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib or osimertinib, have been approved as a first-line treatment for NSCLC patients carrying EGFR-activating mutations and have been shown to greatly improve the prognosis of NSCLC patients (12, 13, 14, 15). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.